CyberSecurity news
FlagThis - #dataprivacy
|
@siliconangle.com
//
OpenAI is facing increased scrutiny over its data retention policies following a recent court order related to a high-profile copyright lawsuit filed by The New York Times in 2023. The lawsuit alleges that OpenAI and Microsoft Corp. used millions of the Times' articles without permission to train their AI models, including ChatGPT. The paper further alleges that ChatGPT outputted Times content verbatim without attribution. As a result, OpenAI has been ordered to retain all ChatGPT logs, including deleted conversations, indefinitely to ensure that potentially relevant evidence is not destroyed. This move has sparked debate over user privacy and data security.
OpenAI COO Brad Lightcap announced that while users' deleted ChatGPT prompts and responses are typically erased after 30 days, this practice will cease to comply with the court order. The retention policy will affect users of ChatGPT Free, Plus, and Pro, as well as users of OpenAI's application programming interface (API), but not those using the Enterprise or Edu editions or those with a Zero Data Retention agreement. The company asserts that the retained data will be stored separately in a secure system accessible only by a small, audited OpenAI legal and security team, solely to meet legal obligations. The court order was granted within one day of the NYT's request due to concerns that users might delete chats if using ChatGPT to bypass paywalls. OpenAI CEO Sam Altman has voiced strong opposition to the court order, calling it an "inappropriate request" and stating that OpenAI will appeal the decision. He argues that AI interactions should be treated with similar privacy protections as conversations with a lawyer or doctor, suggesting the need for "AI privilege". The company also expressed concerns about its ability to comply with the European Union's General Data Protection Regulation (GDPR), which grants users the right to be forgotten. Altman pledged to fight any demand that compromises user privacy, which he considers a core principle, promising customers that the company will fight to protect their privacy at every step if the plaintiffs continue to push for access.
Share:
References :
Classification:
Samiksha Jain@thecyberexpress.com
//
Regeneron Pharmaceuticals is set to acquire the bankrupt genetic testing company 23andMe for $256 million. The deal encompasses 23andMe's Personal Genome Service, Total Health and Research Services business, and its extensive genetic "biobank" of customer data. This acquisition follows a significant data breach and subsequent bankruptcy filing by 23andMe earlier in the year. Regeneron, a leading biotechnology company focused on inventing, developing, and commercializing life-transforming medicines, is primarily interested in leveraging 23andMe's vast genetic data for drug discovery and development.
The acquisition has sparked privacy concerns regarding the handling and security of sensitive genetic data belonging to 23andMe's 15 million customers. This data includes genetic information, health details, genealogy records, and other personal information. Regeneron has pledged to adhere to 23andMe's existing privacy policy, promising to prioritize data privacy, security, and ethical use of customer data. Dr. George Yancopoulos, Regeneron’s president, stated the acquisition will help 23andMe "deliver and build upon its mission to help people learn about their own DNA and how to improve their personal health, while furthering Regeneron’s efforts to improve the health and wellness of many." The bankruptcy court is scheduled to review Regeneron's acquisition on June 17. Concerns have been raised about who would acquire 23andMe's assets in the wake of the data breach and bankruptcy, with some fearing the data could fall into the hands of unethical buyers or even adversarial nations. Regeneron’s pledge to maintain privacy standards and its commitment to working with a court-appointed Customer Privacy Ombudsman aims to ease these concerns. As part of the acquisition, Regeneron will not be acquiring 23andMe’s Lemonaid Health business.
Share:
References :
Classification:
|